Skip to main content
. Author manuscript; available in PMC: 2015 Nov 20.
Published in final edited form as: Cancer Chemother Pharmacol. 2013 Jun 28;72(2):453–461. doi: 10.1007/s00280-013-2219-5

Table 2.

Toxicity, all patients

Toxicity Any grade Grade 3 Grade 4 Grade 5
Hyperglycemia 13 (100 %) 0 0 0
Fatigue 6 (46.2 %) 0 0 0
Hyponatremia 6 (46.2 %) 0 0 0
Bleeding/epistaxis 5 (38.5 %) 0 0 0
Anemia 4 (30.8 %) 0 0 0
Transaminitis 4 (30.8 %) 0 0 0
Lymphopenia 3 (23.1 %) 3 (23.1 %) 0 0
Rash 3 (23.1 %) 0 0 0
Renal dysfunction 3 (23.1 %) 0 0 0
Hypernatremia 3 (23.1 %) 0 0 0
HTN 2 (15.4 %) 2 (15.4 %) 0 0
Hyperbilirubinemia 2 (15.4 %) 0 0 0
Acute MI 1 (7.7 %) 0 0 1 (7.7 %)
Pneumonia 1 (7.7 %) 0 1 (7.7 %) 0
CVA 1 (7.7 %) 0 1 (7.7 %) 0
DVT 1 (7.7 %) 1 (7.7 %) 0 0
Pleural effusion 1 (7.7 %) 1 (7.7 %) 0 0
Syncope 1 (7.7 %) 1 (7.7 %) 0 0
Edema 1 (7.7 %) 0 0 0
Nausea 1 (7.7 %) 0 0 0